[1. H. Jungaberle, S. Thal, A. Zeuch, A. Rougemont-Bücking, M. von Heyden, H. Aicher and M. Scheidegger, Positive psychology in the investigation of psychedelics and entactogens: a critical review, Neuropharmacology142 (2018) 179–199; https://doi.org/10.1016/j.neuropharm.2018.06.03410.1016/j.neuropharm.2018.06.03429964094]Search in Google Scholar
[2. D. E. Nichols, Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens, J. Psychoactive Drugs18 (1986) 305–313; https://doi.org/10.1080/02791072.1986.1047236210.1080/02791072.1986.104723622880944]Search in Google Scholar
[3. L. Iversen, M. White and R. Treble, Designer psychostimulants: pharmacology and differences, Neuropharmacology87 (2014) 59–65; https://doi.org/10.1016/j.neuropharm.2014.01.01510.1016/j.neuropharm.2014.01.01524456744]Search in Google Scholar
[4. R. W. Freudenmann, F. Öxler and S. Bernschneider-Reif, The origin of MDMA (ecstasy) revisited: The true story reconstructed from the original documents, Addiction10 (2006) 1241–1245; https://doi.org//10.1111/j.1360-0443.2006.01511.x10.1111/j.1360-0443.2006.01511.x]Search in Google Scholar
[5. K. S. Leung and L. B. Cottler, Ecstasy and other club drugs: a review of recent epidemiologic studies, Curr. Opin. Psychiatry. 21 (2008) 234–241; https://doi.org/10.1097/YCO.0b013e3282f9b1f110.1097/YCO.0b013e3282f9b1f118382220]Search in Google Scholar
[6. E. Gouzoulis-Mayfrank, Differential actions of an entactogen compared to a stimulant and a hallucinogen in healthy humans, Heffter Rev. Psychodelic Res. 2 (2001) 64–72.]Search in Google Scholar
[7. A. Aouidate, A. Ghaleb, M. Ghamali, S. Chtita, M. Choukrad, A. Sbai, M. Bouachrine and T. Lakhlifi, Combining DFT and QSAR studies for predicting psychotomimetic activity of substituted phenethylamines using statistical methods, J. Taibah. Univ. Sci.10 (2016) 787–796; https://doi.org/10.1016/j.jtusci.2016.07.00110.1016/j.jtusci.2016.07.001]Search in Google Scholar
[8. M. E. Liechti, Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling, Swiss. Med. Wkly.145 (2015) w14043; https://doi.org/10.4414/smw.2015.1404310.4414/smw.2015.1404325588018]Search in Google Scholar
[9. D. M. McDowell and H. D. Kleber, MDMA: its history and pharmacology, Psychiatr. Ann.24 (1994) 127–130.10.3928/0048-5713-19940301-06]Search in Google Scholar
[10. A. C. Parrott, Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy, J. Psychopharmacol.19 (2005) 71–83; https://doi.org/10.1177/026988110504890010.1177/026988110504890015671132]Search in Google Scholar
[11. A. C. Parrott, Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research, Hum. Psychopharmacol.28 (2013) 289–307; https://doi.org/10.1002/hup.231810.1002/hup.231823881877]Search in Google Scholar
[12. T. S. Ray, Constructing the ecstasy of MDMA from its component mental organs: Proposing the primer/probe method, Med. Hypothesis87 (2016) 48–60; https://doi.org/10.1016/j.mehy.2015.12.01810.1016/j.mehy.2015.12.01826826641]Search in Google Scholar
[13. D. E. Nichols, Psychedelics, Pharmacol. Rev. 68 (2016) 264–355; https://doi.org/10.1124/pr.115.01147810.1124/pr.115.011478481342526841800]Search in Google Scholar
[14. F. X. Vollenweider, Brain mechanisms of hallucinogens and entactogens, Dialogues Clin Neurosci.3 (2001) 265–279.10.31887/DCNS.2001.3.4/fxvollenweider]Search in Google Scholar
[15. D. Quinteros-Muñoz, P. Sáez-Briones, G. Díaz-Véliz, S. Mora-Gutiérrez, M. Rebolledo-Fuentes, and B. K. Cassels, Behavioral profiles in rats distinguish among “ecstasy”, methamphetamine and 2,5-dimethoxy-4-iodoamphetamine: Mixed effects for “ecstasy” analogues, Behav. Neurosci.124 (2010) 662–676, https://doi.org/10.1037/a002082710.1037/a002082720939666]Search in Google Scholar
[16. A. Garcia-Romeu, B. Kersgaard and P. H. Addy, Clinical applications of hallucinogens: A Review, Exp. Clin. Psychphamacol. 24 (2016) 229–268; https://doi.org/10.1037/pha000008410.1037/pha0000084500168627454674]Search in Google Scholar
[17. M. C. Mithoefer, M. T. Wagner, A. T. Mithoefer, L. Jerome and R. Doblin, The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment resistant posttraumatic stress disorder: the first randomized controlled pilot study, J. Psychopharmacol.25 (2010) 439–452; http://dx.doi.org/10.1177/026988111037837110.1177/0269881110378371312237920643699]Search in Google Scholar
[18. A. C. Wagner, M. C. Mithoefer, A. T. Mithoefer and C. M. Monson, Combining cognitive-behavioral conjoint therapy for PTSD with 3,4-methylenedioxymethamphetamine (MDMA): A case example, J. Psychoactive Drugs51 (2019) 166–173; https://doi.org/10.1080/02791072.2019.158902810.1080/02791072.2019.158902830890035]Search in Google Scholar
[19. W. Barone, J. Beck, M. Mitsunaga-Whitten and P. Perl, Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD, J. Psychoactive Drugs51 (2019) 199–208; https://doi.org/10.1080/02791072.2019.158080510.1080/02791072.2019.158080530849288]Search in Google Scholar
[20. A. L. Danforth, Embracing neurodiversity in psychedelic science: A mixed-methods inquiry into the MDMA experiences of autistic adults, J. Psychoactive Drugs51 (2019) 146–154; https://doi.org/10.1080/02791072.2019.158711610.1080/02791072.2019.158711630909821]Search in Google Scholar
[21. E. Dyck, Psychedelics and dying care: A historical look at the relationship between psychedelics and palliative care, J. Psychoactive Drugs51 (2019) 102–107; https://doi.org/10.1080/02791072.2019.158130810.1080/02791072.2019.158130830821651]Search in Google Scholar
[22. MDMA Investigator’s Brochure U.S. 10th Edition: 10 July 2018, https://s3-us-west-1.amazonaws.com/mapscontent/research-archive/mdma/MAPS_2018_MDMA_Investigators_Brochure_Edition10_10JUL2018.pdf.]Search in Google Scholar
[23. A. P. Hall and J. A. Henry, Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management, Br. J. Anaesth.96 (2006) 678–685; https://doi.org/10.1093/bja/ael07810.1093/bja/ael07816595612]Search in Google Scholar
[24. M. Ferigolo, A. G. da S. Machado, N. B. Oliveira and H. M. T. Barros, Ecstasy intoxication: the toxicological basis for treatment, Rev. Hosp. Clín. Fac. Med. S. Paulo58 (2003) 332–341.10.1590/S0041-87812003000600008]Search in Google Scholar
[25. M. J. Baggott, K. J. Garrison, J. R. Coyle, G. P. Galloway, A. J. Barnes, M. A. Huestis and J. E. Mendelson, Effects of the psychedelic amphetamine MDA (3,4-methylenedioxyamphetamine) in healthy volunteers, J. Psychoactive Drugs51 (2019) 108–117; https://doi.org/10.1080/02791072.2019.159356010.1080/02791072.2019.1593560]Search in Google Scholar
[26. M. Edland-Gryt, S. Sandberg and W. Pedersen, From ecstasy to MDMA: Recreational drug use, symbolic boundaries, and drug trends, Int. J. Drug Policy5 (2017) 1–8; https://doi.org/10.1016/j.drug-po.2017.07.03010.1016/j.drugpo.2017.07.030]Search in Google Scholar
[27. A. C. Parrott, L. A. Downey, C. A. Roberts, C. Montgomery, R. Bruno and H. C. Fox, Recreational 3,4-methylenedioxymethamphetamine or ‘ecstasy’: current perspective and future research prospects, J. Psychopharmacol.31 (2017) 959–966; https://doi.org/10.1177/026988111771192210.1177/0269881117711922]Search in Google Scholar
[28. R. Bruno, A. J. Matthews, M. Dunn, R. Alati, F. McIlwraith, S. Hickey, L. Burns and N. Sindicich, Emerging psychoactive substance use among regular ecstasy users in Australia, Drug Alcohol Depend.124 (2012) 19–25; https://doi.org/10.1016/j.drugalcdep.2011.11.02010.1016/j.drugalcdep.2011.11.020]Search in Google Scholar
[29. M. D. Krasowski, Drug-assisted Sexual Assaults: Toxicology, Fatality, and Analytical Challenge, in Critical Issues in Alcohol and Drugs of Abuse Testing (Ed. A. Dasgupta), 2nd ed., Academic Press, Elsevier Inc., London 2019, p.p. 225–236.10.1016/B978-0-12-815607-0.00018-6]Search in Google Scholar
[30. H. Kalant, The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs, CMAJ165 (2001) 917–928.]Search in Google Scholar
[31. R. de la Torre, M. Farré, P. N. Roset, C. H. Lopez, M. Mas, J. Ortuño, E. Menoyo, N. Pizarro, J. Segura and J. Cami, Pharmacology of MDMA in humans, Ann. N. Y. Acad Sci.914 (2000) 225–937; https://doi.org/10.1111/j.1749-6632.2000.tb05199.x10.1111/j.1749-6632.2000.tb05199.x]Search in Google Scholar
[32. S. B. Holmes, A. K. Banerjee and W. D. Alexander, Hyponatraemia and seizures after ecstasy use, Postgrad. Med. J. 75 (1999) 32–33; https://doi.org/10.1136/pgmj.75.879.3210.1136/pgmj.75.879.32]Search in Google Scholar
[33. K. A. Graeme, New drugs of abuse, Emerg. Med. Clin. North. Am. 18 (2000) 625–636; https://doi.org/10.1016/S0733-8627(05)70150-410.1016/S0733-8627(05)70150-4]Search in Google Scholar
[34. C. Eiden, P. Cathala, N. Fabresse, Y. Galea, J. C. Mathieu-Daude, E. Baccino and E. H. Peyrière, A case of drug-facilitated sexual assault involving 3,4-methylenedioxy-methylamphetamine, J. Psychoactive Drugs45 (2013) 94–97; https://doi.org/10.1080/02791072.2013.76357310.1080/02791072.2013.76357323662335]Search in Google Scholar
[35. A. L. van Nuijs, S. Castiglioni, I. Tarcomnicu, C. Postigo, M. Lopez de Alda, H. Neels, E. Zuccato, D. Barcelo and A. Covaci, Illicit drug consumption estimations derived from wastewater analysis: a critical review, Sci. Total. Environ.409 (2011) 3564–3577; https://doi.org/10.1016/j.scitotenv.2010.05.03010.1016/j.scitotenv.2010.05.03020598736]Search in Google Scholar
[36. E. Zuccato and S. Castiglioni, Illicit drugs in the environment, Philos. Trans. A Math. Phys. Eng. Sci.367 (2009) 3965–3978; https://doi.org/10.1098/rsta.2009.010710.1098/rsta.2009.010719736230]Search in Google Scholar
[37. S. Karolack, T. Nefau, E. Bailly, A. Solgadi and Y. Levi, Estimation of illicit drugs consumption by wastewater analysis in Paris area (France), Forensic Sci. Int.200 (2010) 153–160; https://doi.org/1016/j.forsciint.2010.04.00710.1016/j.forsciint.2010.04.007]Search in Google Scholar
[38. M. Huerta-Fontela, M. T. Galceran, J. Martin-Alonso and F. Ventura, Occurrence of psychoactive stimulatory drugs in wastewaters in north-eastern Spain, Sci. Total. Environ.397 (2008) 31–40; https://doi.org/10.1016/j.scitotenv.2008.02.05710.1016/j.scitotenv.2008.02.057]Search in Google Scholar
[39. M. S. Lowless, M. Waldman, R. Franczkiewicz and R. D. Clark, Using Chemoinformatics in Drug Discovery, in New Approaches to Drug Discovery, Handbook of Experimental Pharmacology (Eds. U. Nielsch, U. Fuhrmann, S. Jaroch), Springer, Berlin 2015, pp. 232, 139–170.]Search in Google Scholar
[40. C. L. Russom, S. P. Bradbury, S. J. Broderius, D. E. Hammermeister and R. A. Drummond, Predicting modes of toxic action from chemical structure: Acute toxicity in the fathead minnow (Pimephales promelas), Environ. Toxicol.16 (1997) 948–967; https://doi.org/10.1002/etc.562016051410.1002/etc.5620160514]Search in Google Scholar
[41. H. Zhu, A. Tropsha, D. Fourches, A. Varnek, E. Papa, P. Gramatica, T. Oberg, P. Dao, A. Cherkasov and I. V. Tetko, Combinatorial QSAR modeling of chemical toxicants tested against Tetrahymena pyriformis, J. Chem. Inf. Model.48 (2008) 766–784; https://doi.org/10.1021/ci700443v10.1021/ci700443v]Search in Google Scholar
[42. A. Golbamaki, A. Cassano, A. Lombardo, Y. Moggio, M. Colafranceschi and E. Benfenati, Comparison of in silico models for prediction of Daphnia magna acute toxicity, SAR QSAR Environ. Res.25 (2014) 673–694; https://doi.org/10.1080/1062936X.2014.92304110.1080/1062936X.2014.923041]Search in Google Scholar
[43. J. L. Hamelink and A. Spacie, Fish and chemicals: The process of accumulation, Annu. Rev. Pharmacol. Toxicol.17 (1977) 167–177; https://doi.org/10.1146/annurev.pa.17.040177.00112310.1146/annurev.pa.17.040177.001123]Search in Google Scholar
[44. Z. Zhan, L. Li, S. Tian, X. Zhen and Y. Li, Prediction of chemical biodegradability using computational methods, Mol. Simulat.43 (2017) 1277–1290; https://doi.org/10.1080/08927022.2017.132855610.1080/08927022.2017.1328556]Search in Google Scholar
[45. J. Kirchmair, M. J. Williamson, J. D. Tyzack, L. Tan, P. J. Bond, A. Bender and Robert C. Glen, Computational prediction of metabolism: sites, products, SAR, P450. Enzyme dynamics, and mechanisms, J. Chem. Inf. Model. 52 (2012) 617–648; dx.doi.org/10.1021/ci200542m10.1021/ci200542m]Search in Google Scholar
[46. T. T. Abraham, A. J. Barnes, R. H. Lowe, E. A. Kolbrich Spargo, G. Milman, S. O. Pirnay, D. A. Gorelick, R. S. Goodwin and M. A. Huestis, Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans, J. Anal. Toxicol.33 (2009) 439–446; https://doi.org/10.1093/jat/33.8.43910.1093/jat/33.8.439]Search in Google Scholar
[47. C. Burgess, A. Donohoe and M. Gill, Agony and ecstasy: a review of MDMA effects and toxicity, Eur. Psychiatry15 (2000) 287–294; https://doi.org/10.1016/S0924-9338(00)00396-510.1016/S0924-9338(00)00396-5]Search in Google Scholar
[48. R. L. Hartman, N. A. Desrosiers, A. J. Barnes, K. Yun, K. B. Scheidweiler, E. A. Kolbrich-Spargo, D. A. Gorelick, R. S. Goodwin and M. A. Huestis, 3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration, Anal. Bioanal. Chem. 406 (2014) 587–599; https://doi.org/10.1007/s00216-013-7468-y10.1007/s00216-013-7468-y449291624232751]Search in Google Scholar
[49. F. Schifano, A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities, Psychopharmacology173 (2004) 242–248; https://doi.org/10.1007/s00213-003-1730-510.1007/s00213-003-1730-5]Search in Google Scholar
[50. D. Trachsel, M. Hadorn and F. Baumberger, Synthesis of fluoro analogues of 3,4-(methylenedioxy) amphetamine (MDA) and its derivatives, Chem. Biodivers.3 (2006) 326–336; https://doi.org/10.1002/cbdv.20069003510.1002/cbdv.200690035]Search in Google Scholar
[51. R. G. Pearce, R. W. Setzer, J. L. Davis and J. F. Wambaugh, Evaluation and calibration of high-throughput predictions of chemical distribution to tissues, J. Pharmacokinet. Pharmacodyn.44 (2017) 549–565; https://doi.org/10.1007/s10928-017-9548-710.1007/s10928-017-9548-7]Search in Google Scholar
[52. F. Cheng, Y. Ikenaga, Y. Zhou, Y. Yu, W. Li, J. Shen, Z. Du, L. Chen, C. Xu, G. Liu, P. W. Lee, Y. Tang, In silico assessment of chemical biodegradability, J. Chem. Inf. Model. 52 (2012) 655–669; https://doi.org/10.1021/ci200622d10.1021/ci200622d]Search in Google Scholar
[53. L. Moriguchi, S. Hirono, Q. Liu, I. Nakagome and Y. Matsushita, Simple method of calculating octanol/water partition coefficient, Chem. Pharm. Bull.40 (1992) 127–130.10.1248/cpb.40.127]Search in Google Scholar
[54. T. I. Oprea, J. Gottfries, V. Sherbukhin, P. Svensson and T. C. Kuhler, Chemical information management in drug discovery: optimizing the computational and combinatorial chemistry interfaces, J. Mol. Graph. Model.18 (2000) 512–524; https://doi.org/10.1016/S1093-3263(00)00066-810.1016/S1093-3263(00)00066-8]Search in Google Scholar